超声引导下穿刺细胞检测Galectin-3和CK19在良、恶性甲状腺滤泡性肿瘤的表达差异

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the different expression of Galectin-3 and CK19 in benign and malignant thyroid follicular tumors by ultrasound-guided biopsy. Methods: Thirty-four patients with follicular thyroid carcinoma(FTC) and 40 patients with follicular adenoma(FA) were divided into FTC group and FA group respectively. The expression of Galectin-3 and CK19 in the specimens of ultrasound-guided fine needle aspiration cytopathology and in the pathological tissue were detected, analyzed and compared. The expression in the pathological tissue was considered as the gold standard, and then the sensitivity, specificity and accuracy of FNAC specimens to determine Galectin-3 and CK19 were analyzed. The relationship between Galectin-3, CK19 and clinical parameters of patients with FTC were also compared. Results: The expression of Galectin-3 and CK19 between FTC group and FA group were significantly different(Galectin-3：Z=－4.478, P=0.000, CK19：Z=－2.307, P=0.021). The sensitivity, specificity, and accuracy of Galectin-3 and CK19 in FNAC specimens were 85.7%, 76.3% and 81.3% plus 84.7%, 91.2% and 87.5%. The Galectin-3 expression showed no significant difference between the gender, age and tumor size in FTC patients(P>0.05). The positive rate of Galectin-3 in patients with lymph node metastasis(93.3%) and TNMⅢ+Ⅳ(100%) stage were significantly higher than that in patients without lymph node metastasis(63.2%) and TNMⅠ+Ⅱstage(66.7%). The difference was statistically significant(Stages: T=4.359, P=0.037; lymph node metastasis: T=4.242, P=0.039). The expression of CK19 had no significant difference between these clinical parameters(P>0.05). Conclusion: The expression of Galectin-3 and CK19 in FNAC specimens from FTC patients was significantly higher than that in patients with FA, which could help to differentiate FTC and FA in clinics.

Key words： Thyroid neoplasms Galectin 3 Biopsy, fine-needle Ultrasonography, interventional

Received: 03 May 2016

PACS:	Ｒ736.1
	Ｒ445.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Li-qiong
	PAN Jiong
	LI Xiao-qiang

Cite this article:

JIA Li-qiong,PAN Jiong,LI Xiao-qiang. Different expression of Galectin-3 and CK19 in benign and malignant follicular thyroid tumors by ultrasound-guided fine needle aspiration[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(1): 19-22.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2017/V28/I1/19

[1]Ceyran AB, Senol S, Simsek BC, et al. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin[J]. Int J Clin Exp Pathol, 2015, 8(4): 3670-3680.
[2]张久丹，熊金华，王坚. 新型分子标记物对甲状腺滤泡型肿瘤良恶性的鉴别诊断[J]. 中华内分泌代谢杂志， 2013，29（12）：1018-1020.
[3]Sumana BS, Shashidhar S, Shivarudrappa AS. Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms[J]. J Clin Diagn Res, 2015, 9(11): Ec07-11.
[4]Liu Z, Li X, Shi L, et al. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma[J]. Int J Clin Exp Med, 2014, 7(8): 2304-2308.
[5]杨如菊，滕晓东，丁伟，等. MCM2、Ki67、CyclinD1在甲状腺滤泡性癌和滤泡性腺瘤组织中的表达及与Galectin-3、CK19的对比研究[J]. 肿瘤基础与临床，2013，26（6）：464-468.
[6]Falch C, Axt S, Scuffi B, et al. Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer[J]. World J Surg Oncol, 2015, 13(1): 338.
[7]Atik E, Guray M, Gunesacar R, et al. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation[J]. Indian J Cancer, 2014, 51(1): 63-68.
[8]Li C, Dong H, Fu W, et al. Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review[J]. Ann Clin Lab Sci, 2015, 45(6): 707-712.
[9]Ma H, Yan J, Zhang C, et al. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis[J]. Int J Clin Exp Pathol, 2014, 7(11): 7999-8007.
[10]Zhao L, Zhu XY, Jiang R, et al. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma[J]. Int J Clin Exp Pathol, 2015, 8(9): 11236-11247.
[11]刘文胜，张国芬，徐震纲. 119例甲状腺滤泡状癌患者的治疗及预后因素分析[J]. 中华肿瘤杂志，2013，35（10）：778-782.
[12]Toshkezi G, Galgano M, Libohova S, et al. Isolated Spinal Metastasis with Spinal Cord Compression Leads to a Diagnosis of a Follicular Thyroid Carcinoma[J]. Cureus, 2015, 7(10): e346.
[13]黄东航，游振辉，李华水，等. Galectin-3免疫组化检测对甲状腺滤泡性肿瘤良恶性鉴别的意义[J]. 中华内分泌外科杂志，2013，7（5）：424-425.
[14]Wu G, Wang J, Zhou Z, et al. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?[J]. J Int Med Res, 2013, 41(4): 975-983.
[15]Nechifor-Boila A, Borda A, Sassolas G, et al. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases[J]. Pathol Res Prac, 2015, 211(4): 320-325.
[16]Cui W, Sang W, Zheng S, et al. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules[J]. Clin Lab, 2012, 58(7-8): 673-680.
[17]Laco J, Kamaradova K, Vitkova P, et al. Cribriform adenocarcinoma of minor salivary glands may express galectin-3, cytokeratin 19, and HBME-1 and contains polymorphisms of RET and H-RAS proto-oncogenes[J]. Virchows Arch, 2012, 461(5): 531-540.
[18]Lei S, Ding Z, Ge J, et al. Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study[J]. Oncol Lett, 2015, 10(3): 1749-1754.
[19]Paunovic I, Isic T, Havelka M, et al. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors[J]. APMIS, 2012, 120(5): 368-379.